[Form 4] Labcorp Holdings Inc. Insider Trading Activity
Adam H. Schechter, President & CEO and Director of Labcorp Holdings Inc. (LH), reported a sale of company common stock on 08/11/2025. The Form 4 discloses that 5,643 shares were disposed of at a reported price of $266.78 per share pursuant to a plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The filing was executed by an attorney-in-fact on 08/13/2025.
After the reported transaction Schechter beneficially owns 93,319 shares directly. No derivative transactions are reported on this Form 4. The disclosure identifies the transaction code as an S-sale under the stated 10b5-1 plan.
Adam H. Schechter, Presidente & CEO e Direttore di Labcorp Holdings Inc. (LH), ha comunicato la vendita di azioni ordinarie della societ脿 il 08/11/2025. Il Modulo 4 indica che 5,643 azioni sono state cedute al prezzo riportato di $266.78 per azione, in conformit脿 a un piano previsto dalla Rule 10b5-1 del Securities Exchange Act del 1934. La presentazione 猫 stata eseguita da un procuratore il 08/13/2025.
Dopo la transazione segnalata, Schechter possiede direttamente, a titolo beneficiario, 93,319 azioni. Sul Modulo 4 non sono riportate operazioni su derivati. La disclosure indica il codice della transazione come S 鈥� vendita, ai sensi del piano 10b5-1 dichiarato.
Adam H. Schechter, presidente & CEO y director de Labcorp Holdings Inc. (LH), inform贸 la venta de acciones ordinarias de la compa帽铆a el 08/11/2025. El Formulario 4 revela que se dispusieron 5,643 acciones a un precio informado de $266.78 por acci贸n, en virtud de un plan conforme a la Regla 10b5-1 del Securities Exchange Act de 1934. La presentaci贸n fue ejecutada por un apoderado el 08/13/2025.
Tras la transacci贸n informada, Schechter posee de forma beneficiaria directa 93,319 acciones. En este Formulario 4 no se reportan transacciones de derivados. La divulgaci贸n identifica el c贸digo de la transacci贸n como una venta S bajo el mencionado plan 10b5-1.
Labcorp Holdings Inc. (LH)鞚� 靷灔 瓴� CEO鞚挫瀽 鞚挫偓鞚� Adam H. Schechter電� 08/11/2025鞐� 須岇偓 氤错喌欤茧ゼ 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. Form 4鞐愲姅 5,643欤缄皜 欤茧嫻 氤搓碃霅� 臧�瓴� $266.78鞐� 觳橂秳霅橃棃鞙茧┌, 鞚措姅 1934雲� 歃濌秾瓯半灅氩�(Securities Exchange Act of 1934) 鞝� Rule 10b5-1鞐� 霐半ジ 瓿勴殟鞐� 霐半ジ 瓴冹澊霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 鞁犼碃電� 08/13/2025鞐� 雽�毽澑鞚� 鞝滌稖頄堨姷雼堧嫟.
氤搓碃霅� 瓯半灅 鞚错泟 Schechter電� 歆侅爲鞝侅溂搿� 93,319欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚� Form 4鞐愲姅 韺岇儩靸來拡 瓯半灅臧� 氤搓碃霅橃柎 鞛堨 鞎婌姷雼堧嫟. 瓿奠嫓鞐愳劀電� 頃措嫻 瓯半灅 旖旊摐毳� 氇呾嫓霅� 10b5-1 瓿勴殟鞐� 霐半ジ S-毵る弰(S-sale)搿� 響滌嫓頃橁碃 鞛堨姷雼堧嫟.
Adam H. Schechter, pr茅sident & CEO et administrateur de Labcorp Holdings Inc. (LH), a d茅clar茅 la vente d'actions ordinaires de la soci茅t茅 le 08/11/2025. Le Formulaire 4 indique que 5,643 actions ont 茅t茅 c茅d茅es au prix d茅clar茅 de $266.78 par action, conform茅ment 脿 un plan 茅tabli en vertu de la Rule 10b5-1 du Securities Exchange Act de 1934. Le d茅p么t a 茅t茅 effectu茅 par un mandataire le 08/13/2025.
Apr猫s la transaction d茅clar茅e, Schechter d茅tient directement 脿 titre b茅n茅ficiaire 93,319 actions. Aucune transaction sur d茅riv茅s n'est signal茅e dans ce Formulaire 4. La divulgation identifie le code de la transaction comme une vente S au titre du plan 10b5-1 indiqu茅.
Adam H. Schechter, President & CEO und Direktor von Labcorp Holdings Inc. (LH), meldete am 08/11/2025 den Verkauf von Stammaktien des Unternehmens. Aus dem Form 4 geht hervor, dass 5,643 Aktien zu einem gemeldeten Preis von $266.78 je Aktie ver盲u脽ert wurden, und zwar gem盲脽 einem Plan nach Rule 10b5-1 des Securities Exchange Act von 1934. Die Einreichung wurde am 08/13/2025 von einem Bevollm盲chtigten vorgenommen.
Nach der gemeldeten Transaktion besitzt Schechter direkt wirtschaftlich 93,319 Aktien. In diesem Form 4 sind keine Derivatgesch盲fte angegeben. Die Offenlegung weist den Transaktionscode als S鈥慥erkauf im Rahmen des angegebenen 10b5-1鈥慞lans aus.
- Transaction disclosed under Rule 10b5-1, indicating the sale was executed pursuant to a documented trading plan as stated in the filing.
- Timely Form 4 reporting with signature by an attorney-in-fact, providing clear disclosure of the insider transaction and resulting ownership.
- Insider disposed of 5,643 shares, reducing direct beneficial holdings to 93,319 shares as reported.
- No additional context provided in the filing about the origin or intent of the 10b5-1 plan beyond the single explanatory line.
Insights
TL;DR: Routine insider sale disclosed under a 10b5-1 plan; governance disclosure appears complete and timely.
The Form 4 shows a direct sale of 5,643 common shares by Adam H. Schechter on 08/11/2025 at $266.78 per share and cites a Rule 10b5-1 trading plan in the explanation. From a governance perspective, reporting an insider sale executed pursuant to a documented 10b5-1 plan provides transparency on the transaction framework and reduces questions about ad hoc timing. The form also records the reporting signature by an attorney-in-fact, indicating procedural completion of the filing.
TL;DR: Insider sale is disclosed but not large enough on its face to be materially disruptive to share count.
The filing documents a single non-derivative disposition of 5,643 shares by the companys President & CEO, leaving a reported direct beneficial ownership of 93,319 shares. No derivative holdings were reported in Table II. For investors, the key facts are the number of shares sold, the $266.78 reported price, and that the sale was made under a Rule 10b5-1 plan; these details allow market participants to assess size and timing without additional context from the filing itself.
Adam H. Schechter, Presidente & CEO e Direttore di Labcorp Holdings Inc. (LH), ha comunicato la vendita di azioni ordinarie della societ脿 il 08/11/2025. Il Modulo 4 indica che 5,643 azioni sono state cedute al prezzo riportato di $266.78 per azione, in conformit脿 a un piano previsto dalla Rule 10b5-1 del Securities Exchange Act del 1934. La presentazione 猫 stata eseguita da un procuratore il 08/13/2025.
Dopo la transazione segnalata, Schechter possiede direttamente, a titolo beneficiario, 93,319 azioni. Sul Modulo 4 non sono riportate operazioni su derivati. La disclosure indica il codice della transazione come S 鈥� vendita, ai sensi del piano 10b5-1 dichiarato.
Adam H. Schechter, presidente & CEO y director de Labcorp Holdings Inc. (LH), inform贸 la venta de acciones ordinarias de la compa帽铆a el 08/11/2025. El Formulario 4 revela que se dispusieron 5,643 acciones a un precio informado de $266.78 por acci贸n, en virtud de un plan conforme a la Regla 10b5-1 del Securities Exchange Act de 1934. La presentaci贸n fue ejecutada por un apoderado el 08/13/2025.
Tras la transacci贸n informada, Schechter posee de forma beneficiaria directa 93,319 acciones. En este Formulario 4 no se reportan transacciones de derivados. La divulgaci贸n identifica el c贸digo de la transacci贸n como una venta S bajo el mencionado plan 10b5-1.
Labcorp Holdings Inc. (LH)鞚� 靷灔 瓴� CEO鞚挫瀽 鞚挫偓鞚� Adam H. Schechter電� 08/11/2025鞐� 須岇偓 氤错喌欤茧ゼ 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. Form 4鞐愲姅 5,643欤缄皜 欤茧嫻 氤搓碃霅� 臧�瓴� $266.78鞐� 觳橂秳霅橃棃鞙茧┌, 鞚措姅 1934雲� 歃濌秾瓯半灅氩�(Securities Exchange Act of 1934) 鞝� Rule 10b5-1鞐� 霐半ジ 瓿勴殟鞐� 霐半ジ 瓴冹澊霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 鞁犼碃電� 08/13/2025鞐� 雽�毽澑鞚� 鞝滌稖頄堨姷雼堧嫟.
氤搓碃霅� 瓯半灅 鞚错泟 Schechter電� 歆侅爲鞝侅溂搿� 93,319欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚� Form 4鞐愲姅 韺岇儩靸來拡 瓯半灅臧� 氤搓碃霅橃柎 鞛堨 鞎婌姷雼堧嫟. 瓿奠嫓鞐愳劀電� 頃措嫻 瓯半灅 旖旊摐毳� 氇呾嫓霅� 10b5-1 瓿勴殟鞐� 霐半ジ S-毵る弰(S-sale)搿� 響滌嫓頃橁碃 鞛堨姷雼堧嫟.
Adam H. Schechter, pr茅sident & CEO et administrateur de Labcorp Holdings Inc. (LH), a d茅clar茅 la vente d'actions ordinaires de la soci茅t茅 le 08/11/2025. Le Formulaire 4 indique que 5,643 actions ont 茅t茅 c茅d茅es au prix d茅clar茅 de $266.78 par action, conform茅ment 脿 un plan 茅tabli en vertu de la Rule 10b5-1 du Securities Exchange Act de 1934. Le d茅p么t a 茅t茅 effectu茅 par un mandataire le 08/13/2025.
Apr猫s la transaction d茅clar茅e, Schechter d茅tient directement 脿 titre b茅n茅ficiaire 93,319 actions. Aucune transaction sur d茅riv茅s n'est signal茅e dans ce Formulaire 4. La divulgation identifie le code de la transaction comme une vente S au titre du plan 10b5-1 indiqu茅.
Adam H. Schechter, President & CEO und Direktor von Labcorp Holdings Inc. (LH), meldete am 08/11/2025 den Verkauf von Stammaktien des Unternehmens. Aus dem Form 4 geht hervor, dass 5,643 Aktien zu einem gemeldeten Preis von $266.78 je Aktie ver盲u脽ert wurden, und zwar gem盲脽 einem Plan nach Rule 10b5-1 des Securities Exchange Act von 1934. Die Einreichung wurde am 08/13/2025 von einem Bevollm盲chtigten vorgenommen.
Nach der gemeldeten Transaktion besitzt Schechter direkt wirtschaftlich 93,319 Aktien. In diesem Form 4 sind keine Derivatgesch盲fte angegeben. Die Offenlegung weist den Transaktionscode als S鈥慥erkauf im Rahmen des angegebenen 10b5-1鈥慞lans aus.
FAQ
What did Adam H. Schechter report on the Labcorp (LH) Form 4?
How many Labcorp (LH) shares does Adam Schechter own after the transaction?
Was the sale by Adam Schechter part of a pre-arranged trading plan?
Are there any derivative transactions reported in this Form 4 for Labcorp (LH)?
Who signed the Form 4 for Adam H. Schechter?
